Clinical Trial Update: Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) [Phase 1]

View source ↗

Summary

Phase 1 study of ADCT-402 in relapsed or refractory B-cell lineage non-Hodgkin lymphoma completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Lymphoma Follicular
• Lymphoma Large B-cell Diffuse
• Lymphoma Mantle-cell
• Lymphoma Marginal Zone
• Mediastinal B-cell Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• ADCT-402

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Non-Hodgkin Lymphoma, Burkitt's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-04-13